Molecular Imaging Biomarkers for Oncology Clinical Trials

被引：55
|
作者：
Mankoff, David A. [1 ]
Pryma, Daniel A. [1 ]
Clark, Amy S. [2 ]
机构：
[1] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2014年 / 55卷 / 04期
关键词：
cancer biomarkers; clinical trials; cancer therapy; BREAST-CANCER; FDG-PET; TRASTUZUMAB; CRITERIA;
D O I：
10.2967/jnumed.113.126128
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Biomarkers can be used to characterize disease status or predict disease behavior. Cancer biomarkers have typically relied on assays of blood or tissue; however, molecular imaging has a promising and complementary role as a cancer biomarker. This "Focus on Molecular Imaging" article reviews the current role of biomarkers to direct cancer clinical trials and clinical practice, along with current and future cancer biomarker applications of molecular imaging.
引用
收藏
页码：525 / 528
页数：4
相关论文
共 50 条
  • [21] The Role of Clinical Trials in Veterinary Oncology
    Burton, Jenna
    Khanna, Chand
    VETERINARY CLINICS OF NORTH AMERICA-SMALL ANIMAL PRACTICE, 2014, 44 (05) : 977 - +
  • [22] Clinical Trials and Personalized Medicine in Oncology?
    Arnold, Dirk
    Bokemeyer, Carsten
    ONKOLOGIE, 2010, 33 : 25 - 29
  • [23] The clinical trials crisis in gynecologic oncology
    del Carmen, Marcela G.
    Annunziata, Christina M.
    Rice, Laurel W.
    GYNECOLOGIC ONCOLOGY, 2017, 145 (03) : 481 - 482
  • [24] Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials
    Shukla-Dave, Amita
    Obuchowski, Nancy A.
    Chenevert, Thomas L.
    Jambawalikar, Sachin
    Schwartz, Lawrence H.
    Malyarenko, Dariya
    Huang, Wei
    Noworolski, Susan M.
    Young, Robert J.
    Shiroishi, Mark S.
    Kim, Harrison
    Coolens, Catherine
    Laue, Hendrik
    Chung, Caroline
    Rosen, Mark
    Boss, Michael
    Jackson, Edward F.
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2019, 49 (07) : E101 - E121
  • [25] Association between treatment toxicity and outcomes in oncology clinical trials
    Abola, M. V.
    Prasad, V.
    Jena, A. B.
    ANNALS OF ONCOLOGY, 2014, 25 (11) : 2284 - 2289
  • [26] Endpoints for clinical trials and revised assessment in neuro-oncology
    Butowski, Nicholas
    Chang, Susan M.
    CURRENT OPINION IN NEUROLOGY, 2012, 25 (06) : 780 - 785
  • [27] Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology
    Glimelius, B.
    Lahn, M.
    ANNALS OF ONCOLOGY, 2011, 22 (08) : 1717 - 1725
  • [28] Quantitative PET/CT Scanner Performance Characterization Based Upon the Society of Nuclear Medicine and Molecular Imaging Clinical Trials Network Oncology Clinical Simulator Phantom
    Sunderland, John J.
    Christian, Paul E.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (01) : 145 - 152
  • [29] Intraoperative molecular imaging clinical trials: a review of 2020 conference proceedings
    Azari, Feredun
    Kennedy, Gregory
    Bernstein, Elizabeth
    Hadjipanayis, Constantinos
    Vahrmeijer, Alexander L.
    Smith, Barbara L.
    Rosenthal, Eben
    Sumer, Baran
    Tian, Jie
    Henderson, Eric R.
    Lee, Amy
    Quyen Nguyen
    Gibbs, Summer L.
    Pogue, Brian W.
    Orringer, Daniel A.
    Charalampaki, Cleopatra
    Martin, Linda W.
    Tanyi, Janos L.
    Lee, Major Kenneth
    Lee, John Y. K.
    Singhal, Sunil
    JOURNAL OF BIOMEDICAL OPTICS, 2021, 26 (05)
  • [30] Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI
    Caroli, Anna
    Prestia, Annapaola
    Wade, Sara
    Chen, Kewei
    Ayutyanont, Napatkamon
    Landau, Susan M.
    Madison, Cindee M.
    Haense, Cathleen
    Herholz, Karl
    Reiman, Eric M.
    Jagust, William J.
    Frisoni, Giovanni B.
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2015, 29 (02): : 101 - 109
12345